Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
about
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
P2860
Q28079372-BB7FAE74-176C-478D-A30C-F48F7FE91A93Q30241189-81BB3BA8-F378-4D8E-B1C6-680974ABEA58Q33841334-FD989467-75CD-4F01-AB0D-65CC995B5368Q36389384-8D5D6F90-2CAC-4795-9745-EA6A9DAEA0F9Q36983860-0A22ECEE-91A0-44D2-80F4-ABC742BFF61EQ38642952-22ECE0D7-6DEA-410B-BFF4-A2425767BF2DQ39186183-C3CD9F4F-2BE2-46C0-A8B3-88391A71273FQ41348012-61632C19-0103-4F62-82E6-2A14B6F248BFQ47135575-58A707D2-61A3-4D72-9986-CF8D7391F1E0Q48253155-2C592676-28F8-411B-B8E5-B652BA560299Q48275281-C8D56A1C-D993-4E93-96DE-C34117EE9391Q52641875-5FBC9D24-0CC2-48F9-8B3A-1EBA26A2A72FQ55003649-698480D7-FE96-424F-AE3E-56754B5C26F7Q58791422-EE87CE68-04B4-438F-860C-38B2ACA62F3F
P2860
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
type
label
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
prefLabel
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
P2093
P1433
P1476
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
P2093
Carlos Graux
Christian Chatelain
François Mullier
Jean-Michel Dogné
P304
P356
10.1001/JAMAONCOL.2015.5932
P577
2016-02-04T00:00:00Z